A Pan-Cancer Analysis of the Oncogenic Role of CD276 in Human Tumors
Lilong Liu, Zhipeng Yao, Yiting Liu, Yang Li, Yuhong Ding, Junyi Hu, Zhenghao Liu, Pengjie Shi, Ke Chen, Zheng Liu, Wenhao Zhang, Yaxin Hou · 2024
Read A Pan-Cancer Analysis of the Oncogenic Role of CD276 in Human Tumors by Lilong Liu, Zhipeng Yao, Yiting Liu, Yang Li, Yuhong Ding, Junyi Hu, Zhenghao Liu, Pengjie Shi, Ke Chen, Zheng Liu, Wenhao Zhang, Yaxin Hou (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11675885.txt.
Description
Lilong Liu and a team of co-authors assess a protein called CD276 across many cancers in a 2024 paper. The protein, also known as B7-H3, belongs to a family that shapes immune responses and has been tied to tumor growth. No study had yet judged its role across cancers as a whole, so the team mine several databases.
They find high CD276 levels link to tumor advance and poor survival in most cancers. Tumors with high levels drew in more support cells that suppress immunity and fewer killer T cells. The authors argue the protein helps tumors grow by building a suppressive setting, making it a candidate marker and target.
Catalog record
| CREATOR | Lilong Liu, Zhipeng Yao, Yiting Liu, Yang Li, Yuhong Ding, Junyi Hu, Zhenghao Liu, Pengjie Shi, Ke Chen, Zheng Liu, Wenhao Zhang, Yaxin Hou |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 20 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |